ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

September 14, 2007 17:14 ET

ART Advanced Research Technologies Inc. Files Preliminary Short form Prospectus for Common Share Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

MONTREAL, CANADA--(Marketwire - Sept. 14, 2007) - ART Advanced Research Technologies Inc. ("ART")(TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce today that it has filed a preliminary short form prospectus with the securities regulatory authorities in each of the provinces of Canada for a public offering of common shares.

The underwriting syndicate is led by Desjardins Securities Inc. and also includes Demers Conseil Inc.

ART intends to use the net proceeds of the offering for the commercialization, sale and distribution of the Company's products, including the Optix® and SoftScan® systems, and for the development of new products and applications, as well as for working capital and general corporate purposes.

The transaction is subject to the receipt of all necessary regulatory and stock exchange approvals.

This news release is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States in the absence of registration or pursuant to an exemption from registration. Any public offering of securities made in the United States will be made by means of a prospectus that may obtained from the issuer or selling security holder and will contain detailed information about the company and management, as well as financial statements.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in ART's regulatory filings, including the aforementioned preliminary short form prospectus, available on SEDAR (www.sedar.com).

Contact Information

  • ART ADVANCED RESEARCH TECHNOLOGIES INC.
    Jacques Bedard
    Chief Financial Officer
    514-832-0777
    jbedard@art.ca